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Hepaticdifferentiationof patient-derived inducedpluripotent stemcells
(iPSCs) constitutes a unique in vitro approach to analyze hepatic biology in
the context of thegenetic backgroundof thepatient, and could alsohold the
key to the large production of hepatocytes for autologous transplantation.
Several protocols of hepatic differentiation of human hPSCs have been
described recently (Basma et al., 2009; Si Tayeb et al., 2010; Sullivan et al.,
2010). They rely on a multi-step process in which the treated cells go
through a deﬁnitive endoderm stage induced by treatment of colony-type
culture of hiPSCwith Activin A, followed by hepatic speciﬁcation to commit
the cells toward the hepatic lineage. Finally cells are matured in vitro to
obtain albumin-positive cells, which structurally look like mature hepato-
cytes. Functional assays demonstrate that these hepatocytes-like cells
(HLCs) also secrete albumin,metabolizeurea, recapitulate lipidmetabolism,
and express various isoforms of the cytochrome p450.
These differentiated HLCs retain a strong fetal and immature pheno-
type, as demonstrated by the persistence of alpha-fetoprotein (AFP) and
diminished hepatic functions when compared to primary adult hepato-
cytes (PHHs). Strategies to improve the differentiation protocol are
being explored. For example, treatment of differentiated cells with
small-molecule compounds may hold the key to improving hepatic
maturation or functionality (Shan et al., 2013). However, in order toarpentier),
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ss article under the CC BY-NC-ND licscreen for small molecules, the differentiation protocol needs to bemin-
iaturized to 384-well plates.
Thus far, the efﬁcient differentiation of hPSCs has relied on a prelimi-
nary colony-type culture of hPSCs, directly treated to produce hepato-
cytes without passage at any stage of the hepatic differentiation
(Hannan et al., 2013; Mallanna and Duncan, 2013). Using this approach,
efﬁcient differentiation of hPSC-derived HLCs is usually limited to 6-,
12- or 24-well plates, curtailing the usefulness of this approach in gener-
ating cell populations suitable for high-throughput assay (Reviewed in
Schwartz et al., 2014). Somepublished protocols suggested passing deﬁn-
itive endoderm (DE) cells (Hay et al., 2008; Agarwal et al., 2008; Liu et al.,
2010; Duan et al., 2010), to allow a more homogeneous and ﬂatter cell
population (Inamura et al., 2011), but none of them took advantage of
this approach to miniaturize the format of plates. Furthermore the HLCs
tend to lose their differentiated phenotypewith timewithout special cul-
turing condition (Khetani and Bhatia, 2008). Here we describe a protocol
allowing efﬁcient and consistent differentiation of hESC and hiPSC into
functional hepatocyte-like cells in 96- and 384-well plates. We also de-
scribe a new HLC culturing condition, allowing maintenance of SC-
derived HLCs for more than 3 weeks in these high-throughput formats,
with a gradual improvement of their hepatic phenotype and functions.
2. Results
2.1. Limitations of current differentiation protocol
Our previously published protocol (Carpentier et al., 2014), adapted
from Basma et al. (Basma et al., 2009) described efﬁcient differentiationense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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allowed us to obtain HLCs with up to 80% of hepatic markers (AFP,
ALB and/or AAT)-positive cells, but exhibited several limitations in
terms of homogeneity of the HLCs population and miniaturization to
smaller-well format (Fig. 1). First hPSCs were routinely maintained in
a colony-type culture and passaged in aggregates. The deﬁnitive endo-
derm (DE) induction was thus performed on 70–80% conﬂuent large
SC colonies treated with 100 ng/ml of Activin A and bFGF in the pres-
ence of increasing concentrations of FCS (Basma et al., 2009). While
allowing up to 60–80% of cells expressing SOX17 and FOXA2 after
3 days of treatment in the best case, this protocol was hampered by a
high variability in efﬁciency of DE induction, because of variability with-
in the lots of Activin A. Moreover, it usually led to a non-homogeneousFig. 1.Detailed previousprotocolwith itsmain limitations. Colony-type cultures of hPSCswere d
seeded onMatrigel, before undergoing hepatic speciﬁcation andmaturation. Onewell of a 6-we
ALB(±) HLCs growing around DE-derived aggregates. Our detailed improved protocol can be finduction of SOX17/FOXA2-positive DE cells. Importantly, OCT4-
positive cells within the DE cell population were still observed at the
end of the DE induction stage.
Before inducing hepatic speciﬁcation, we reported that it is prefera-
ble to pass the DE cells. Indeed in our hands, direct hepatic speciﬁcation
on conﬂuent DE cells led to overcrowded cell population affecting both
the maturation and visualization of the differentiated cells. When pas-
saged, our DE cells exhibited the same limitations as colony-type
hPSCs and could not be re-seeded at a single cell level. To allow repro-
ducible and consistent survival of the cells, DE cells had to be passed
in a similar way to colony-type hPSCs: re-suspending and re-plating ag-
gregates of approximately 20–50 DE aggregated cells. Treatment with
high concentration of HGF and DMSO then induced proliferation ofifferentiated into deﬁnitive endodermpopulation.DE cellswere then passed in aggregates,
ll plate of hPSCswould usually produces 3wells of a 6-well plate of heterogeneous AFP(+)
ound in Fig. 7.
642 A. Carpentier et al. / Stem Cell Research 16 (2016) 640–650hepatoblast-like cells expanding from those aggregates, leading to a
typical non-homogeneous hepatoblast population. Only those expand-
ed monolayer of AFP-positive cells had the ability to maturate into
albumin-positive cells after dexamethasone treatment (Fig. 1).
In this context, attempts to pass and differentiate DE cells in 96-well
plates were inefﬁcient with heterogeneous cell density and gave rise to
inconsistent differentiation from wells to wells. It was also difﬁcult to
quantify level of differentiation by IFA of albumin-positive cells because
of large cell aggregates.
Next we describe several improvements of our previously published
protocol at the different stages from SC culture to hepatic differentia-
tion, allowing for the ﬁrst time efﬁcient, homogeneous, consistent and
reproducible generation of hPSC-derived HLCs in 384-well plates.
2.2. Non-colony-type culture of human pluripotent stem cells
Colony-type culture remains today the standardmethod tomaintain
hPSCs in culture. Colony-type culture however presents some disad-
vantages, such as the heterogeneous state of SCs within colonies
(Fig. 2A) and common occurrence of chromosomal abnormalities.
Recently, Chen et al. described a protocol to adapt human pluripo-
tent SCs to a robust and reliable non-colony type culture (Chen
et al., 2012). This approach is based on repeated passage of the
hPSCs at single-cell level using gentle dissociation buffer (Accutase),
and seeding and maintaining in the presence of high concentration
of Y-27632 Rock Inhibitor to reduce the high death rate of individual
SCs. After a few passages, hPSCs adapted to a single-cell culture are
selected and display the same characteristics as hPSCs cultured in
colony, in terms of pluripotency and self-renewal.Fig. 2. Adaptation of hPSCs to non-colony type culture. (A) Colony-type culture of hiPSC showi
and hiPSCs was adapted to a non-colony type culture, by serial passages at a single-cell level, u
lower panels show contrast phase picture of hiPSC monolayer and merged picture of con
morphology and maintained their expression of pluripotency markers (OCT4). More detailed
hPSCs is shown in Supplemental Fig. 1.In this context, we used an H9-ESC-derived cell line, named H9ESC-
ml (for monolayer), adapted for non-colony type culture by Chen et al.
(2012). We also adapted several of our own iPSC cell lines, generated
using STEMCCA lentiviruses (Carpentier et al., 2014), to a non-colony
type culture following Chen's protocol. Cell morphology (large nucleus,
nucleoli) and expression of various pluripotent markers were assessed
routinely in the adapted cells to ensure the maintenance of their
pluripotency functions, by IFA, FACS analysis or RTqPCR (Fig. 2B and
Supplemental Fig. 1).
Non colony-type hPSCswere routinely cultured inmTeSR1onhighly
concentrated (0.4 mg/ml) growth factor-reduced Matrigel, with daily
medium change, and were passed using gentle dissociation buffer (for
example, StemPro® Accutase®) in mTeSR1 containing 10 μM Rock In-
hibitor Y-27632.2.3. Induction of homogeneous deﬁnitive endoderm population
Induction of DE from hPSCs is a critical ﬁrst step for subsequent efﬁ-
cient hepatic differentiation. Different protocols of induction of DE have
been described in the past, all of them relying on treatment with high
concentration of Activin A (D'Amour et al., 2005). In order to improve
our previously described DE induction protocol (Carpentier et al.,
2014), we hypothesized that our non-colony type SC would allow a
more homogeneous distribution of the cells and then a more homoge-
neous effect of AA. Conﬂuent hESCs or hiPSCs were resuspended at a
single-cell level using Accutase, and 2 million single cells were seeded
on low concentration GF (−) Matrigel (0.125 mg/ml) in presence of
Y-27632. On the day after, the cells formed a homogeneous monolayerng area of loss of pluripotency marker OCT4 expression. (B) Colony-type culture of H9ESC
sing gentle dissociation buffer and high concentration of Rock Inhibitor (Y-27632). The 2
trast phase and OCT4 immunostaining. Monolayer adapted hPSCs exhibited SC-like
characterization of expression of pluripotency markers in monolayer-adapted culture of
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tion of Activin A on the SC population.
We previously experienced a high variability of effect of Activin A
from lot to lot. In order to obtain a more robust and more reproducible
DE induction, we investigated the efﬁciency of the STEMdiff™ Deﬁn-
itive Endoderm Kit (from StemCell Technologies) on our non-colony
type hESCs and hiPSCs, following the manufacturer's instruction. At
the end of the DE induction, the treated cells formed a homogeneous
and conﬂuent monolayer of individualized DE cells without aggre-
gates or multicellular structures (Fig. 3A). The expression of deﬁni-
tive endoderm markers SOX17 and FOXA2/HNF3B was assessed by
immunoﬂuorescence or by FACS analysis. Around 98% of both
hiPSC- and hESC-derived cells were positive for both markers,
assessed by IFA (Fig. 3B) and ﬂow cytometry (Fig. 3C), and expres-
sion of pluripotency (OCT4) was negative (data not shown),
conﬁrming a very efﬁcient induction of DE cells on both types of
hPSCs investigated here. Each well of a 6-well plate contained be-
tween 2 and 2.5 million DE cells. Despite cellular toxicity of Activin
A observed during the ﬁrst few days of DE induction, the cell prolif-
eration during days 3 and 4 allows the maintenance of high number
of cells. To be noted, some hiPSC cell lines exhibited higher cell tox-
icity or a slow cell growth during the DE induction, leading to b2mil-
lion cells per well at the end of the induction.
2.4. Passage of DE cells in various culture formats before hepatic speciﬁcation
In our previous protocol, hepatic speciﬁcation could be per-
formed only on passaged aggregates of DE cells, leading to a hetero-
geneous hepatoblast population (Fig. 1). We reasoned that adapting
hPSCs to single-cell level and treating single hPSCs for homogeneousFig. 3. Deﬁnitive endoderm induction of non-colony-type hPSCs. (A) After 4 days of induction, 2
homogeneous monolayer cell population (no aggregates). (B) Co staining for hiPSCs-derived D
very few cells remain negative for these 2markers (Arrow).(C) FACS analysis of H9-ESCs-DE cel
passage before starting hepatic speciﬁcation. See Supplemental Fig. 2 for details about assessinDE induction would allow efﬁcient passage of the DE cells at a single
cell level.
At the end of the homogeneous DE induction (see Fig. 3 for valida-
tion), the cell monolayer was resuspended using Accutase, and resus-
pended in our ‘differentiation medium’ (DMEM-F12, 10% KOSR, 1%
NEAA, 1% glutamine, 1% PS) in the presence of 100 ng/ml of HGF, 1% di-
methyl sulfoxide (DMSO) and 10 μMY-27,632. Our experiencewith dif-
ferentiation in 6- and 12-w plates showed us that a passage of 1 in 3
usually led to the best level of hepatic differentiation at the end of the
differentiation process. To further investigate this optimal concentra-
tion of cells, we seeded increasing amounts of H9 ESCs-derived DE
cells in wells of 384w plates, and differentiation was carried out as de-
scribed in this manuscript. At the end of the hepatic maturation (Day
15), hepatic differentiation efﬁciency was assessed by quantiﬁcation of
the number of AFP- and ALB-positive cells, and quantiﬁcation of secret-
ed AFP and ALB in the supernatant during the last day of differentiation
(Supplemental Fig. 2A and B). Representative results for the H9-hESC
cell line showed that both percentage of positive cells and secretion of
ALB (normalized to the number of cells, assessed by automatic quantiﬁ-
cation of nuclei) exhibit a higher hepatic maturity when about 4000 DE
cells were seeded per well (Supplemental Fig. 2A and C). We then rou-
tinely resuspended H9-derived DE cells at a concentration of 125,000
cells per ml, subsequently seeding them at a density of about 79.000
cells/cm2 (see Supplemental Table 1 for volume and cell number per
well depending of the plate format).
Importantly, the optimal cell concentration varied from cell line to
cell line, and should be evaluated for each cell line using the strategy de-
scribed here. For example, one of our iPSC cell lines had optimal hepatic
differentiation when seeded at 10,000 DE cells per well (data not
shown).million hESCS or hiPSCs should produce 2–2.5million conﬂuent DE cells, forming a highly
E markers FOXA2 and SOX17, conﬁrming the co-expression of these 2 DE markers, while
ls conﬁrming that 98% are positive for DEmarker SOX17. At that time, DE cells are ready for
g optimal DE seeding density.
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After seeding of the optimized density of DE cells per cm2 and incu-
bation overnight at 37 °C, the hepatic speciﬁcation was continued for 7
more days by culturing the cells in thedifferentiationmediumwith high
concentration of hepatocyte growth factor (HGF, 100 ng/ml) in pres-
ence of 1% DMSO, with daily medium change, as described previously
(Basma et al., 2009; Carpentier et al., 2014). At that point, cells do not
undergo apoptosis further and Rock Inhibitor is no longer required.
Within days, the cells proliferated and reached conﬂuence, until a
point when they became growth arrested.
The exact role of DMSO in this protocol is unclear but is critical. It has
been suggested that DMSO promotes hepatic differentiation (Hay et al.,
2008; Sullivan et al., 2010), through desacetylation of histones (Baxter
et al., 2010) and/or by inducing methylation of the cellular DNA
(Basma et al., 2009). DMSO may also stabilize cell membranes (Duan
et al., 2010). Importantly, it has been reported (Hay et al., 2008) that
subsets of SC remaining within the DE population can lead to other
cell type differentiation when cultured in presence of DMSO. This em-
phasizes the importance of having the purest DE cell population before
starting hepatic speciﬁcation.
At day 12 of differentiation (8 days of hepatic speciﬁcation), the cells
formed a conﬂuent monolayer (Fig. 4A). They do not display charac-
teristic hepatocyte morphology yet and thus cell differentiation can-
not be validated by phase contrast observation only: the nuclei
appeared more oval than round, with an intermediate ratio cyto-
plasm/nucleus. Thus the hepatic speciﬁcation had to be assessed by
IFA for the expression of early hepatic markers, like the hepatocyte
nuclear factor 4 A (HNF4A), a master regulator of hepaticFig. 4. Hepatic speciﬁcation andmaturation of DE cells passed and differentiated inwells of a 96
did not display a hepatocyte morphology (phase contrast, magniﬁcation: 10×). Cells we
immunoﬂuorescence (Magniﬁcation: 20×). (B) After hepatic maturation (day 15), hepatic-li
10×) and were positive for AFP, albumin and HNF4A (magniﬁcation: 20×). (C) Activity of th
Luc\\IPA) in HLCs compared to hPSCs. (D) Hep-Par1 immunohistochemistry visualization of e
uPA/SCID/Bg mice. See Supplemental Fig. 3 for more functional characterization of HLCs and adifferentiation, and alpha-fetoprotein (AFP), marker of fetal
hepatoblasts. In our protocol, more than 90% of the cells were posi-
tive for these 2 markers by IFA (Fig. 4A). The cells were also positive
for alpha-1-antitrypsin (AAT) (data not shown). Importantly, the
cells were negative for albumin or different cytochrome p450 iso-
forms, markers of more mature hepatocytes. The level of hepatic
speciﬁcation could also be assessed by ELISA. High levels of secreted
AFP but no albumin could be detected in the supernatants of culture
at day 12 of differentiation (Data not shown).
2.6. Hepatic Maturation
On day 12, the differentiation medium containing HGF and DMSO
was removed and the cells were then cultured for 3 more days in the
differentiation medium containing 10−7 M dexamethasone (DEX), a
synthetic glucocorticoid, in order to induce hepaticmaturation. Theme-
dium was replaced daily. As described in our previous protocol, treat-
ment with DEX induced a drastic change of morphology within
2 days, the cells becoming polygonal, displaying tight junctions and
small round nuclei (Fig. 4B). Lipid droplets were also apparent in the
cell cytoplasm. The hepatic maturation of the cells was assessed by im-
munoﬂuorescence assays. HLCs displayed characteristic nuclear stain-
ing for HNF4A and 3B, and strong cytoplasm expression of AFP, ALB
(Fig. 4B) and AAT (data not shown).
We then assessed hepatic functions of HLCs (Supplemental Fig. 1).
Secretion of albumin (ALB) is a common indication of hepatic matura-
tion. After 3 days of culture with DEX, the treated cells secrete signiﬁ-
cant amounts of ALB, conﬁrming hepatic maturation of the cells
(Supplemental Fig. 1A). We also investigated the effect of Oncostatin-well plate. (A) After 8 days of hepatic speciﬁcation (day 12), the cells were conﬂuent, but
re positive for HNF4A and AFP, but remained negative for albumin, as assessed by
ke cells (HLCs) displayed typical polygonal morphology (phase contrast, magniﬁcation:
e cytochrome P450 3 A family (Substrate: Luc\\PFBE) and CYP3A4 isoform (Substrate:
ngrafted HLCs 14 days after intrasplenic injection of 4 million HLCs in the spleen of MUP-
ssessment of intra-hepatic engraftment.
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2008; Si Tayeb et al., 2010; Sullivan et al., 2010), or in combination
with DEX (Agarwal et al., 2008; Liu et al., 2010) to induced hepatic mat-
uration of hepatoblasts into HLCs. Treatment with OSM did not show
additional effect on maturation induced by DEX, conﬁrming our previ-
ous observations (Supplemental Fig. 3A). Hepatic cells are also involved
in lipid metabolism: lipid storage in the HLCs was conﬁrmed by Oil Red
O staining of lipid droplets (Supplemental Fig. 3B), and their capacities
to uptake lipoproteins was demonstrated by incubation with Alexa
488-conjugated LDL (Supplemental Fig. 3C). The hepatic storage of gly-
cogen was assessed by periodic acid Schiff staining (Supplemental
Fig. 3D). Finally we observed uptake of Indocyanin Green (ICG), a pro-
cess mediated by the anion transporter LSAT1 speciﬁcally expressed
by mature hepatocytes (Supplemental Fig. 3E).
More importantly, we assessed the metabolism of PFBE, a drug me-
tabolized by the CYP3A cytochromes, a major family of liver detoxifying
enzymes, by our cells. After incubation in presence of Luciferin-PFBE,
the release of Luciferin in the supernatant of culture conﬁrmed that
our cells have active CYP3A (Fig. 4C, left panel). In order to more specif-
ically address the activity of the CYP3A4, a marker of mature hepato-
cytes, we incubated our HLCs with a CYP3A4-speciﬁc substrate
Luciferin-IPA. Release of Luciferin in this assay conﬁrms the activity of
the CYP3A4 in our cells (Fig. 4C, right panel).
At this stage of differentiation, hPSC-ml-derived HLCs could also be
efﬁciently engrafted in the liver of transgenic MUP-uPA/SCID/Bg mice,
as described previously (Carpentier et al., 2014). Within days after
intrasplenic injection, increasing levels of human albumin could be de-
tected in the serum of injected mice (data not shown), suggesting re-
population of the mouse liver by the human HLCs. Engrafted HLCsFig. 5. Assessment of hepatic maturation of H9-ESC-derived HLC differentiated in 384-well pla
within a well of a 384-well plate. Higher magniﬁcation illustrates the polygonal morpho
quantiﬁcation of percentage of cells positive for hepatic markers AFP, AAT and ALB within w
wells (magniﬁcation 4×). (C) ELISA for AFP and ALB in the supernatants during the differentiacould also be visualized in situ by IHC (Fig. 4D, negative control illustrat-
ed in Supplemental Fig. 3F) and by IFA (Supplemental Fig. 3G).
2.7. Efﬁcient and reproducible hepatic differentiation in 384-well plates
The advantage of this differentiation protocol is to be able to passage
homogeneous DE cells in smaller plate format than the standard plate
format necessary to maintained hPSC culture and treat them with
Activin A. In this context, we investigated the efﬁciency of our protocol
for hepatic differentiation in plate format compatible with high
throughput assay: 384-well plates. As mentioned earlier, a cell density
of 79,000 DE cells per cm2 would correspond to 4400 H9 hESC-
derived DE cells per well. This number of resuspended DE cells, previ-
ously generated in 6-well plate, was seeded in multiple wells of a 384-
well plate previously coated with GF(−) Matrigel, and hepatic speciﬁ-
cation andmaturationwere performed as described previously. This ap-
proach allowed us to obtain in every well homogeneous monolayer of
polygonal cells covering the entire well, without aggregates or empty
areas (Fig. 5A). After IFA staining for hepatic markers, the percentage
of positive cells at day 15 of differentiation was assessed by automated
image acquisition, showing a consistent high percentage of AFP(+),
AAT(+) and ALB(+) from well to well (Fig. 5B). CV% for expression of
markers assessed on more than 100 wells by automatic acquisition
and analysis show variability below 15%. The IFA results were further
conﬁrmed by ELISA. At day 15, AFP secretion is maintained at a similar
level as Day 12, conﬁrming that the HLCs did not lose expression of
fetal markers. However, different from Day 12 cells, the HLCs now se-
creted signiﬁcant level of ALB (Fig. 5C), conﬁrming efﬁcient maturation
of HLCs in wells of 384-well plates. In order to calculate the CV% for thetes. (A) Phase contrast microscopy showing homogeneous population of polygonal cells
logy, small round nuclei and presence of cytoplasmic lipid droplets. (B) Automatic
ells of a 384-well plate, with quantiﬁcation evaluated automatically on more than 100
tion process in 384-well plates.
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Elmer),with CV% ranging between 5 (rawdata) and 15% (quantiﬁcation
using standard curves). These results conﬁrm the homogeneous hepatic
differentiation of hPSCs within wells of 384-well plate with phenotypic
and functional variability low enough to make it suitable for high-
throughput assay.2.8. Long-term maintenance of HLCs
We usually maintained the HLCs in a medium previously used for
primary culture of adult human hepatocytes (Podevin et al., 2010) and
hPSC-derived HLCs (Hay et al., 2008; Sullivan et al., 2010; Carpentier
et al., 2014), composed of Leibowitz L15 medium, 8.4% FCS, 8.4%
Tryptose Phosphate Buffer, 1% NEAA and PS, complemented with 1 μM
of insulin (5.8 μg/ml) and 10 μM (4.8 μg/ml) of hydrocortisone 21-
hemisuccinate. However, in thismedium, HLCs usually exhibit a charac-
teristic phenotypic instability, with a loss of hepatic morphology within
a week, associated with a dedifferentiation of the cells. For example, we
showed that HCV-infected HLCs lost the ability to support viral replica-
tion during this dedifferentiation process (Carpentier et al., 2014).Fig. 6. Long-termmaintenance of HLCs. (A) Improved phenotypic stability whenHLCs are cultu
medium. (B) Immunoﬂuorescence assays for expression of AFP and ALB in HLCs, differentiate
binucleated cells). Table indicates percentage of positive cells at the different times of culture
variation (CV%) from well to well. (C) Relative secretion of AFP and ALB assessed by ELISA in
3 weeks in the WEM medium. (D) RTqPCR analysis of hepatic genes in SC-derived HLCs, d
Supplemental Fig. 2 for expression relative to control PHHs. (E) Co-immunostaining for ALB,
medium. (F) Increased of the CYP3A PFBE and CYP3A4 IPA activities during 3 weeks of cultu
light blue bars) and 384-well plates (black and blue bars). (G) HCV replication in HLCs
extracellular HCV RNA quantiﬁcation, expressed respectively as log10 (copies HCV RNA/mg to
compared to non-inoculated HLCs (red line). HLCs were differentiated, inoculated with HCVccIn order to improve the stability of the differentiated hepatocytes, we
investigated the culture of HLCs in a medium validated for primary cul-
ture of adult human hepatocytes (Schulze-Bergkamen et al., 2003) and
also used for in vitro differentiation and long-term maintenance of
HepaRG cells, a mature hepatic cell model based on in vitromaturation
of precursor hepatic-like cells (Lucifora et al., 2014). This medium is
based on William's E Medium, containing 10% FBS, penicillin and strep-
tomycin, complemented with 1 μg/ml of human insulin (0.17 μM),
10 μM of hydrocortisone 21-hemisuccinate (4.8 μg/ml) and 1.8%
DMSO. When cultured in this WEM medium, the HLCs displayed a
much more stable phenotype, with differentiated HLCs maintained in
culture for more than 3 weeks (Fig. 6A and B). Interestingly, the typical
hepatic morphology of the HLCs continues to improve toward more po-
lygonal cellswith smaller nucleus andmore binucleated cells (Fig. 6B, ar-
rows). What promotes this phenotypic stability is not known, but the
DMSO in the WEM culture medium has been described as critical for
maintenance of primary hepatocytes phenotype (Schulze-Bergkamen
et al., 2003) and also helps stabilize cellular membrane (Duan et al.,
2010). Moreover, speciﬁc concentration of insulin and hydrocortisone
has been shown to maintain hepatic phenotype of primary cultures of
human adult hepatocytes for around 15 days (Podevin et al., 2010).red in the newWEMhepaticmaintenancemedium, compared to previously described L15
d in 384-well plates, and maintained for 3 weeks in the WEMmedium. (Arrows indicate
in WEM medium, assessed by automatic quantiﬁcation, and their respective coefﬁcient of
the supernatants of culture of HLCs, differentiated in 384w plates, and maintained for
ifferentiated in 24-well plates, and maintained for 3 weeks in the WEM medium. See
AFP, CYP3A4 and CYP2D6 in HLCs, differentiated in 24-well plates, after 21 days in WEM
re in WEM medium, on HLC differentiated and maintained in 24-well plates (grey and
maintained in WEM medium for up to 1 month, assessed by RT-qPCR for intra- and
tal cellular RNA) (black line) and log10 (copies HCV RNA/ml of supernatants) (grey line),
and maintained in 24-well plates.
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during the 3 weeks of maintenance in the WEM medium by immu-
noﬂuorescence followed by automatic quantiﬁcation of the positive
cells showed a maintained expression of AFP (N80%) and a progres-
sive increased percentage of cells positive for albumin (From 58% to
up to 73%) (Fig. 6B). To be noted, not only more cells were positive
for albumin, but also the intensity of albumin staining per cell was
signiﬁcantly increased while AFP staining intensity tended to de-
crease. These results were further conﬁrmed by a consistent in-
crease of albumin concentration in the supernatant (Fig. 6C).
Secretion of AFP decreased during the 2nd and 3rd week of culture
in the hepatic maintenance medium (Fig. 6C).
RTqPCR analysis of hepatic genes during culture in the WEMmedi-
um shows that ALB mRNA is signiﬁcantly increased during the
3 weeks of culture (Fig. 6D, green line), consistentwith results obtained
by IFA and ELISA. Importantly, we could also detect an increased expres-
sion of CYP3A4mRNA (Fig. 6D, red line), marker of mature hepatocyte.
To be noted, the expression of the fetalmarker AFP and CYP3A7, the pre-
dominant human fetal liver cytochrome, did not increase during that
time (Fig. 6D, yellow and orange lines). However, when compared to
RNA isolated from primary culture of adult hepatocytes, HLCs still ex-
hibited a lessmature phenotype (Supplemental Fig. 4). Immunoﬂuores-
cence assays on cells maintained 21 days in the WEM medium show
that cells brightly positive for ALB are also positive for CYP3A4
(Fig. 6E, upper panels). Interestingly, expression of CYP2D6 was also
correlated to ALB bright positive cells (Fig. 6E, middle panels), but
found mainly in cells negative for AFP (Fig. 6E, lower panels).
Assessment of the CYP3A family activity during culture in the WEM
medium conﬁrmed an improved activity during the 3 weeks of culture
in the WEM medium, both in 24w- and 384w-HLCs (Fig. 6F). Because
CYP3A7 is not overexpressed during that time, we believe that this in-
crease of CYP3A activity is mainly due to CYP3A4. This hypothesis was
conﬁrmed by increased activity of the CYP3A4 activity, assessed by in-
cubating the HLCs with Luc\\IPA, and observed both in 24w- and
384w-HLCs (Fig. 6F). To be noted, attempts to quantify induction of
CYP3A4 by Rifampicin (25 to 100 µM) and CYP1A2 by Omeprazole
(50 to 200 µM) in HLCs differentiated in 384w plates were not success-
ful (data not shown), suggesting that further maturation is needed to
ensure fully mature hepatic functionality of these cells in 384w plates.
Finally, we investigated the maintenance of HCV replication after
overnight inoculation of HLCs with JFH1-HCVcc (Wakita et al., 2005),
followed by culture in the WEM medium for a month (Fig. 6G). While
HLCs maintenance in our previous L15 culture medium showed loss of
HCV replication (Carpentier et al., 2014), culture in the WEM medium
allowed maintenance of HCV replication, demonstrated by quantiﬁca-
tion of both intracellular and extracellular HCV RNA for more than a
month.
Taken together, these results illustrate the functional maintenance
of hPSC-derived HLCs for more than 3 weeks, with an improvement of
their hepatic functions (ALB secretion, CYP3A4 activity), and the ability
tomaintain long-term infection byHCV, a hepatotropic virus notorious-
ly difﬁcult to culture.
3. Discussion
Here we described for the ﬁrst time the efﬁcient and reproducible
differentiation of human pluripotent stem cells into functional
hepatocyte-like cells in 384-well plates. We identiﬁed here several crit-
ical factors that ensure efﬁciency and reproducibility of hepatic differen-
tiation of hPSCs (Fig. 7):
- The use of hPSCs maintained in non-colony type culture, allowing a
better andmore homogeneous passage of the cells at the pluripotent
stage.
- The use of the STEMdiff Deﬁnitive Endoderm kit, which combined
with the single-cell culture adapted hPSCs, allows a robust andreproducible induction of highly pure and homogeneous DE cell
population.
- The passage of monolayer hPSC-derived DE cells at a single-cell
level, allowing subsequent differentiation in smaller-well for-
mats (96- and 384-well plates)
- A hepatic speciﬁcation step in presence of DMSO, allowing amore
homogeneous hepatic differentiation but also a proliferation of
the passaged cells to reach conﬂuence.
While the HLCs generated from this new protocol do not exhibit a
signiﬁcantly more mature hepatic phenotype than what has been de-
scribed before, we described here for the ﬁrst time the consistent and
reproducible differentiation of HLCs in 384-well plates, which opens
the door to their use for high throughput assay. Importantly, we showed
here that results for both phenotypic (expression of hepatic markers by
IFA) and functional (secretion of ALB assessed by AlphaLISA) character-
ization of the 384w-HLCs show coefﬁcients of variation below 15%,
making them suitable as readout for high-throughput screening. In
this context, the screening for compounds that could improve the
level of in vitromaturation of HLCs is currently in progress. Recently, a
study used micro patterned PHHs (MCPPs) on feeder cells to perform
a high-throughput screen in order to identify drugs capable of improv-
ing functionality in vitro of PHHs and potentially promotingmaturation
of SC-derivedHLCs (Shan et al., 2013). However this screenwasnot per-
formed directly on HLCs, because they could not be efﬁciently differen-
tiated in wells smaller than a 24-well plate. Only candidate drugs
selected on adult PHHs were then validated on HLCs, suggesting that
drugs speciﬁcally acting on early stages of hepatic maturation could
have been missed.
In addition,we described a new long-term culturemedium allowing
maintenance and further maturation of HLCs for more than 3 weeks in
384-well plates. During maintenance in WEMmedium, HLCs exhibited
improved phenotypic stability, increased secretion and higher percent-
age of cells positive for adult hepatic markers. Importantly, CV% of ex-
pression of hepatic markers, like AFP and ALB, was maintained below
15% throughout the maintenance in WEM medium, compatible with
use for high-throughput assay.
HLCs maintained inWEMmedium also demonstrated an increase of
themetabolic activity of CYP3A family and3 A4 cytochromes, consistent
with a more mature phenotype. However, CYP activity showed signiﬁ-
cant variability from well to well, with CV% above 15%. Investigation
for compounds improving hepatic maturation should also focus on
their effect on homogeneity of maturation, in order to allow high
throughput assay related to more mature hepatic functions, like drug
metabolism and toxicology assays.
Finally, we demonstrated that HLCs maintained in WEM medium
could support productive HCV infection for more than 30 days, suggest-
ing it could be a valuable approach for studying the HCV infection in
cells reproducing the genetic background of the patient. To be noted,
HLCs maintained in WEM medium also support and maintain produc-
tive infection by hepatitis B virus (HBV) after in vitro infection (Xia Y
et al., unpublished data).
Taken together, these improvements allow for the ﬁrst time the pro-
duction of stem cell-derived HLCs in a format suitable for high-
throughput assays. PHHs are currently the reference cells for liver me-
tabolism in vitro assay and toxicology studies, but PHHs-based ap-
proaches are hampered by very limited cell supply, short-term in vitro
culture, and lack of speciﬁc donor's phenotypic and genetic information.
The ability to reprogram patient somatic cells into hiPSCs and then to
differentiate them into hepatocyte-like cells, and maintain them for
more than 3 weeks in 384-w plates opens for the ﬁrst time the possibil-
ity to generate large numbers of patient-speciﬁc hepatocytes for high-
throughput assay. However, more improvements are still needed to de-
velop a stem cell-derived hepatocyte-like cells model as relevant and
mature as adult hepatocytes. In this context, we are currently
conducting a high throughput screen of thousands of small compounds
Fig. 7.Optimized protocol for differentiation of hPSCs into HLCswithin wells of a 384-well plate. Non-colony-type cultures of hPSCs are differentiated into highly homogeneous deﬁnitive
endodermpopulation. DE population homogeneity is assessed for co-expression of SOX17 and FOXA2. DE cells are then passed at a single-cell level on GF(−)Matrigel, before undergoing
hepatic speciﬁcation and maturation in a 384-well plate. At the different stage of hepatic speciﬁcation and maturation, cells should be assessed for expression of hepatoblast marker AFP
and hepatocyte marker ALB. One well of a 6-well plate of hPSCs usually produces over 1 full 384-well plate of highly homogeneous AFP(+) ALB(+) HLCs.
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ated in 384-well plates. We hope that this strategy, based on the new
protocol described here, will identify new compounds aimed at improv-
ing the relevance of the model.
4. Experimental procedures
4.1. Stem cell culture
Experiments were performed on several iPSC cell lines generated
in our laboratory (using STEMCAA-lentivirus reprograming vector)
or by other collaborating teams here at NIH, using retro- andlentiviruses. In parallel, protocol of differentiation was validated
using the H1, H9 and HSF6 ESC cell lines. All hESCs and hiPSCs cell
lines were maintained in a colony-type culture on growth factor-
reduced (GF(−)) Matrigel (0.125 mg/ml)(Corning) in mTeSR1
(StemCell Technologies). Colony type H9-ESC and 2 STEMCCA-
iPSCs were then adapted to a non-colony type culture following in-
structions by Chen et al. (Chen et al., 2012). Brieﬂy, hPSC colonies
were dissociated using Accutase (Life Technologies) and single
hPSCs were resuspended in mTeSR1 (StemCell technologies) in the
presence of 10 μM of Rock Inhibitor Y-27,632 (Millipore) and seeded
in wells coated with highly concentrated GF(−) Matrigel (0.4 mg/ml).
Monolayer type hPSCs are routinely passed 1 in 8 every 5–6 days.
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PFA4% and incubated overnight with antibodies anti-OCT4 (Santa
Cruz Biotechnologies, sc-9081, 1:400) or anti-NANOG (BD, N31-355,
1:200) as described previously (Carpentier et al., 2014). FACS analysis
were performed on resuspended cells as described previously
(Carpentier et al., 2014) using the same set of antibodies. Total
RNA was also isolated from monolayer and colony type culture of
hPSCS using the GeneJET RNA isolation kit (Thermo Scientiﬁc) and
pluripotency gene expression was assessed using the Verso 1-step
QRT-PCR Low ROX kit (Thermo Scientiﬁc).
4.2. Deﬁnitive endoderm induction
DE was induced using the STEMdiff™ Deﬁnitive Endoderm Kit
(StemCell Technologies), following manufacturer's instructions. Brieﬂy,
monolayer type culture of hPSCs are resuspended using Accutase (Life
Technologies) and 2 million cells were seeded per well of a 6w plates
previously coated with GF(−) Matrigel (0.125 mg/mL). The day after,
cell monolayer was washed with PBS and then cultured for 4 days in
STEMdiff Deﬁnitive Endoderm Basal medium with Supplements A and
B (for 1 day) and then Supplement B only (for 3 days, with daily medi-
um change). Expression of DEmarkerswas assessed by immunoﬂuores-
cence assay and ﬂow cytometry on PFA-ﬁxed cells using a combination
of antibodies against SOX17 (R&D Systems, AF1924, 1:100) and FOXA2
(Santa Cruz Biotechnology, sc-271,103, 1:100) as described previously
(Carpentier et al., 2014).
4.3. Hepatic speciﬁcation
Before starting the hepatic speciﬁcation, DE cells have to be passed.
DE cells were resuspended using accutase, and seeded at a concentra-
tion of 79,000 cells/cm2 (See Supplemental Table 1), in a differentiation
medium (High glucose DMEM, F12, 10% KOSR, 1% Glutamine, 1% NEAA,
1% Penicillin/Streptomycin)(Life technologies) containing 100 ng/ml of
HGF (Peprotech), 1%DMSO (SigmaAldrich) and 10 μMRock Inhibitor Y-
27,632. The day after, the medium is changed, and the cells are cultures
for 7 more days in Differentiation Medium containing similar concen-
tration of HGF and DMSO, but without Rock Inhibitor Y-27,632.
4.4. Hepatic maturation
Hepatoblasts are then maturated for 3 days by culturing the cells in
differentiation medium containing 10−7 M of Dexamethasone (Sigma
Aldrich).
4.5. HLCs long-term maintenance
DifferentiatedHLCs could then bemaintained formore than 3weeks
in theWEMmedium based onWilliam's EMedium containing 10% FBS,
1% PS, 1 μg/ml of human Insulin (0.17 μM) (Sigma Aldrich), 4.8 μg/ml of
hydrocortisone 21-hemisuccinate (10 μM) (Sigma Aldrich), and 1.8%
DMSO, with medium changed every 2-3 days.
4.6. Primary Human Hepatocytes culture
Suspension of freshly isolated or cryopreserved PHHs were seeded
on Matrigel andmaintained for 2 days in hepatic maintenance medium
before their total RNAwas isolated and used as control for expression of
hepatic genes in HLCs. PHHs were provided by the NIH-funded Liver
Tissue Procurement and Cell Distribution System (N01-DK-7-0004/
HHSN26700700004C).
4.7. Assessment of hepatic differentiation and maturation
Secretion of ALB (Bethyl Laboratories) and AFP (Calbiotech) were
assessed by ELISA following manufacturer's instructions. To be noted,when assessing AFP secretion inWEMmedium, the supernatant should
be diluted at least 1:100 as theWEMmediumaffect the sensitivity of the
kit. Secretion of ALB in 384-well plates was also assessed by AlphaLISA
(Perkin-Elmer), following manufacturer's instructions. For immunoﬂu-
orescence assay, cells were ﬁxed using PFA 4%, and stained using a com-
bination of antibodies anti-ALB (Cedarlane, CL2513A, 1:330), anti-AFP
(Sigma Aldrich, A8452, 1:330), anti-AAT (Dako, A0012, 1:50), anti-
HNF4A (Santa Cruz Biotech, sc-6556, 1:100), anti-CYP3A4 (Abcam,
ab135813, 1:50) and anti-CYP2D6 (Sigma Aldrich, AV41675, 1:200).
Percentage of positive cells was then assessed using an Image Express
Micro (Molecular Devices) and analyzed with Metamorph Cell Scoring
software. Total RNA was isolated using the GeneJET RNA isolation kit
(Thermo Scientiﬁc) and gene expression was assessed using the Verso
1-step QRT-PCR Low ROX kit (Thermo Scientiﬁc). Used primers are
listed in Supplemental Table 2. Functional assays (ORO staining, Lipo-
protein uptake, PAS staining and ICG metabolism) were performed as
described previously (Carpentier et al., 2014). CYP450 3A family activity
was assessed using the P450-Glo Luc\\PFBE CYP3A4 Assay (Promega),
and speciﬁc CYP3A4 activity was conﬁrmed using the P450-Glo
Luc\\IPA CYP3A4 Assay (Promega), both following the manufacturer's
instructionswith Luc\\PFBE and Luc\\IPA diluted in differentiationme-
dium instead of WEMmedium.
Murine hepatic transplantation of human HLCs was performed in
the MUP-uPA/SCID/Bg transgenic mouse model, by intrasplenic injec-
tion of 4 million HLCs dissociated using Trypsin–EDTA (Corning) and
re-suspended in Saline Buffer, as described previously (Carpentier
et al., 2014). In situ detection of engrafted cells was performed on PFA-
ﬁxed section of parafﬁn-embedded liver, using antibodies anti-Hep
Par-1 (Dako, M7158, 1:50), anti-ALB (Bethyl Laboratories, A80-229A,
1:500) and anti-AAT (Dako, A0012, 1:50), as described previously
(Carpentier et al., 2014).4.8. In vitro HCV infection
HCV infection was performed using JFH1-HCVcc (Genotype 2a),
produced in Huh7.5.1 cells as described by Wakita et al. (Wakita
et al., 2005). HLCs were incubated overnight with JFH1-HCVcc at a
multiplicity of infection of 0.5. The day after, inoculated cells were
washed with PBS and maintained in culture in WEM medium.
Every 3 days, HCV RNAs were isolated from HLCs using the GeneJET
RNA isolation kit (Thermo Scientiﬁc) and from supernatants using
the GeneJET Viral DNA and RNA Puriﬁcation Kit (Thermo Scientiﬁc).
HCV RNA titer was then quantiﬁed by RT-qPCR as described previ-
ously (Carpentier et al., 2014).4.9. Statistics
In vitro data are expressed as average of at least 3 independent
experiments, and 2-tailed Student's t-test was performed to assess
statistical signiﬁcance. A P value of b0.05 was considered signiﬁcant.
Results concerning the 384-well plate experiments are expressed
as average of at least 100 wells. The coefﬁcient of variation (CV%) is
calculated as:
CV% ¼ Standard deviation of N100 individual values½ =
Average of N100 values½ :4.10. Animal study approval
HLCmouse engraftmentwas performed according to the NIH guide-
lines for animal care andwas approved by the Ofﬁce of Animal Care and
Use, Bethesda, Maryland, USA (protocol NIDDK-K090-LDB-13).
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